Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide, but no effective pharmacological therapeutics are available for clinical use. Nonalcoholic steatohepatitis (NASH) is the more severe stage of NAFLD. During this progress, dysregulation of endoplasmic reticulum (ER) related pathways and proteins is one of the predominant hallmarks. Here, we aimed to reveal the role of RNF5, an ER-localized E3 ubiquitin-protein ligase, in NASH and to explore its underlying mechanism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach and Results</h3><p>We firstly inspected the expression level of RNF5 and found that RNF5 was markedly decreased in livers with NASH in multispecies including human. We then introduced adenoviruses for Rnf5 overexpression or knockdown into primary mouse hepatocytes, and found that palmitic acid/oleic acid (PAOA)-induced lipid accumulation and inflammation in hepatocytes were markedly attenuated by Rnf5 overexpression but exacerbated by <i>Rnf5</i> gene silencing. Hepatocyte-specific <i>Rnf5</i> knockout significantly exacerbated hepatic steatosis, inflammatory response and fibrosis in mice challenged with diet-induced NASH. Mechanistically, we identified HRD1 as a novel binding partner of RNF5 by systematic interactomics analysis. RNF5 directly bound to HRD1 and promoted its lysine 48 (K48)- and K33-linked ubiquitination and subsequent proteasomal degradation. Furthermore, Hrd1 overexpression significantly exacerbated PAOA-induced lipid accumulation and inflammation, and shRNA-mediated <i>Hrd1</i> knockdown exerted the opposite effects. Notably, <i>Hrd1</i> knockdown significantly disminished PAOA-induced lipid deposition and upregulation of related genes resulted from Rnf5 ablation in hepatocytes. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These data indicate that RNF5 inhibits NASH progression by targeted degradation HRD1 for ubiquitin- mediated proteasomal pathway. Targeting the RNF5-HRD1 axis may provide new insights in the pathogenesis of NASH, and pave the way for developing novel strategies for NASH prevention and treatment.</p></section>

Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling

Hepatic regulator of G protein signaling 14 ameliorates NAFLD through activating cAMP-AMPK signaling by targeting Giα1/3

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin‐Mediated Degradation of 3‐Hydroxy‐3‐Methylglutaryl CoA Reductase Degradation Protein 1

Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

P38γ modulates the lipid metabolism in non‐alcoholic fatty liver disease by regulating the JAK–STAT signaling pathway

Ginsenoside Rg5 inhibits lipid accumulation and hepatocyte apoptosis via the Notch1 signaling pathway in NASH mice

Regulator of G‐protein signaling 14 protects the liver from ischemia–reperfusion injury by suppressing TGF‐β‐activated kinase 1 activation

Loss of Regulator of G Protein Signaling 5 Exacerbates Obesity, Hepatic Steatosis, Inflammation and Insulin Resistance

LncRNA GAS5 Knockdown Mitigates Hepatic Lipid Accumulation via Regulating MiR-26a-5p/PDE4B to Activate cAMP/CREB Pathway

RNA helicase DEAD‐box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling

Ginsenoside Rg1 exerts anti‐apoptotic effects on non‐alcoholic fatty liver cells by downregulating the expression of SGPL1

FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP‐activated protein kinase–Caspase 6 signal axis

Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function

Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats

Tumor Necrosis Factor α–Induced Protein 8–Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta–Activated Kinase 1 Activation

Activation of PGC ‐1α via isoliquiritigenin‐induced downregulation of miR ‐138‐5p alleviates nonalcoholic fatty liver disease